Related Experiment Video
Updated: Jun 15, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
[Recent and future development of anti-HIV agents]
Masayuki Amano1, Hiroaki Mitsuya
1Department of Hematology, Kumamoto University Graduate School of Medicine.
Since the first acquired immune deficiency syndrome (AIDS) patient reported over 25 years ago, a number of antiretroviral agents have been generated for the fight with AIDS. Combination chemotherapy combining such antiretroviral agents has had a major impact on the morbidity and mortality of AIDS patients. However, we have faced multiple major problems in AIDS therapy. Those problems represent the challenges different than we faced in the development of the first drug. We are obviously at a new forefront in the therapy of HIV infection. Further improved approaches to explore new treatment modalities should be continued in the hope that with new and more potent antiviral agents, we will be able to control HIV diseases more efficiently and effectively.
Since the first acquired immune deficiency syndrome (AIDS) patient reported over 25 years ago, a number of antiretroviral agents have been generated for the fight with AIDS. Combination chemotherapy combining such antiretroviral agents has had a major impact on the morbidity and mortality of AIDS patients. However, we have faced multiple major problems in AIDS therapy. Those problems represent the challenges different than we faced in the development of the first drug. We are obviously at a new forefront in the therapy of HIV infection. Further improved approaches to explore new treatment modalities should be continued in the hope that with new and more potent antiviral agents, we will be able to control HIV diseases more efficiently and effectively.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
